Alberto Aiolfi1, Emanuele Asti1, Emanuele Rausa1, Daniele Bernardi1, Gianluca Bonitta1, Luigi Bonavina2. 1. Department of Biomedical Science for Health, Division of General Surgery IRCCS Policlinico San Donato, University of Milan, Piazza Edmondo Malan, 1, 20097, Milan, Italy. 2. Department of Biomedical Science for Health, Division of General Surgery IRCCS Policlinico San Donato, University of Milan, Piazza Edmondo Malan, 1, 20097, Milan, Italy. luigi.bonavina@unimi.it.
Abstract
BACKGROUND: Trans-oral endoscopic access to the pancreaticobiliary system is challenging after Roux-en-Y gastric bypass (RYGB). Trans-gastric ERCP (TG-ERCP) has emerged as a viable option to manage patients with symptomatic post-RYBG choledocolithiasis. The aim of this systematic review and meta-analysis was to examine the outcomes of TG-ERCP to better define the risk-benefit ratio of this procedure and to guide clinical decision-making. METHODS: A literature search was conducted to identify all reports on ERCP after RYGB. Pubmed, MEDLINE, Embase, and Cochrane databases were thoroughly consulted matching the terms "ERCP" AND "gastric bypass." Pooled prevalence of ERCP success rate, ERCP-related morbidity, post-procedural infectious complications, and overall morbidity were calculated using Freeman-Tukey double arcsine transformation and DerSimonian-Laird estimator in random effect meta-analysis. Heterogeneity among studies was evaluated using I2-index and Cochrane Q test. Meta-regression was used to address the effect of potential confounders. RESULTS: Thirteen papers published between 2009 and 2017 matched the inclusion criteria. Eight hundred fifty patients undergoing 931 procedures were included. The most common clinical indications for TG-ERCP were biliary (90%) and pancreatic (10%). The majority of patients underwent an initial laparoscopic approach (90%). Same-day ERCP was successfully achieved in 703 cases (75.5%). Pooled prevalence of ERCP success rate, ERCP-related morbidity, post-procedural infectious complications, and overall morbidity were 99% (95% CI = 98-100%), 3.1% (95% CI = 1.0-5.8%), 3.4% (95% CI = 1.7-5.5%), and 14.2% (95% CI = 8.5-20.8%), respectively. CONCLUSION: TG-ERCP is a safe and effective therapeutic option in patients with symptomatic post-RYGB choledocolithiasis.
BACKGROUND: Trans-oral endoscopic access to the pancreaticobiliary system is challenging after Roux-en-Y gastric bypass (RYGB). Trans-gastric ERCP (TG-ERCP) has emerged as a viable option to manage patients with symptomatic post-RYBG choledocolithiasis. The aim of this systematic review and meta-analysis was to examine the outcomes of TG-ERCP to better define the risk-benefit ratio of this procedure and to guide clinical decision-making. METHODS: A literature search was conducted to identify all reports on ERCP after RYGB. Pubmed, MEDLINE, Embase, and Cochrane databases were thoroughly consulted matching the terms "ERCP" AND "gastric bypass." Pooled prevalence of ERCP success rate, ERCP-related morbidity, post-procedural infectious complications, and overall morbidity were calculated using Freeman-Tukey double arcsine transformation and DerSimonian-Laird estimator in random effect meta-analysis. Heterogeneity among studies was evaluated using I2-index and Cochrane Q test. Meta-regression was used to address the effect of potential confounders. RESULTS: Thirteen papers published between 2009 and 2017 matched the inclusion criteria. Eight hundred fifty patients undergoing 931 procedures were included. The most common clinical indications for TG-ERCP were biliary (90%) and pancreatic (10%). The majority of patients underwent an initial laparoscopic approach (90%). Same-day ERCP was successfully achieved in 703 cases (75.5%). Pooled prevalence of ERCP success rate, ERCP-related morbidity, post-procedural infectious complications, and overall morbidity were 99% (95% CI = 98-100%), 3.1% (95% CI = 1.0-5.8%), 3.4% (95% CI = 1.7-5.5%), and 14.2% (95% CI = 8.5-20.8%), respectively. CONCLUSION: TG-ERCP is a safe and effective therapeutic option in patients with symptomatic post-RYGB choledocolithiasis.
Authors: Mitchal A Schreiner; Lily Chang; Michael Gluck; Shayan Irani; S Ian Gan; John J Brandabur; Richard Thirlby; Ravi Moonka; Richard A Kozarek; Andrew S Ross Journal: Gastrointest Endosc Date: 2012-01-31 Impact factor: 9.427
Authors: Kevin L Grimes; Victor H Maciel; Wilmer Mata; Gabriel Arevalo; Kirpal Singh; Maurice E Arregui Journal: Surg Endosc Date: 2014-10-16 Impact factor: 4.584
Authors: Raj J Shah; Maximiliano Smolkin; Roy Yen; Andrew Ross; Richard A Kozarek; Douglas A Howell; Gennadiy Bakis; Sreenivasan S Jonnalagadda; Abed A Al-Lehibi; Al Hardy; Douglas R Morgan; Amrita Sethi; Peter D Stevens; Paul A Akerman; Shyam J Thakkar; Brian C Brauer Journal: Gastrointest Endosc Date: 2013-01-03 Impact factor: 9.427
Authors: Erik Bowman; Jacob Greenberg; Michael Garren; Nalini Guda; Brian Rajca; Mark Benson; Patrick Pfau; Anurag Soni; Andrew Walker; Deepak Gopal Journal: Surg Endosc Date: 2016-01-28 Impact factor: 4.584
Authors: Christophe Snauwaert; Pierre Laukens; Bruno Dillemans; Jacques Himpens; Danny De Looze; Pierre Henri Deprez; Abdenor Badaoui Journal: Endosc Int Open Date: 2015-06-23
Authors: Harry Martin; Tareq El Menabawey; Orla Webster; Constantinos Parisinos; Michael Chapman; Stephen P Pereira; Gavin Johnson; George Webster Journal: Frontline Gastroenterol Date: 2021-02-24
Authors: Lieke M Koggel; Peter J Wahab; Rob J Robijn; Theo J Aufenacker; Bart P L Witteman; Marcel J M Groenen; Jan M Vrolijk Journal: Obes Surg Date: 2020-08-23 Impact factor: 4.129
Authors: Alberto Machado da Ponte-Neto; Wanderley M Bernardo; Lara M de A Coutinho; Iatagan Rocha Josino; Vitor Ottoboni Brunaldi; Diogo T H Moura; Paulo Sakai; Rogério Kuga; Eduardo G H de Moura Journal: Obes Surg Date: 2018-12 Impact factor: 4.129